How I treat elderly patients with myeloma

被引：35

作者：

Mehta, Jayesh ^{[1
]}

Cavo, Michele ^{[2
]}

Singhal, Seema ^{[1
]}

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[2] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

来源：

BLOOD | 2010年 / 116卷 / 13期

关键词：

STEM-CELL TRANSPLANTATION; RELAPSED MULTIPLE-MYELOMA; LENALIDOMIDE PLUS DEXAMETHASONE; HIGH-DOSE CHEMOTHERAPY; QUALITY-OF-LIFE; AUTOLOGOUS TRANSPLANTATION; INITIAL THERAPY; THALIDOMIDE; MELPHALAN; TRIAL;

D O I：

10.1182/blood-2009-10-163329

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The clinical approach to older patients with myeloma has to be modified to take into account comorbidities and the likelihood of higher treatment-related toxicity. Individualization of management and adequate supportive therapy are important to obtain the best response while minimizing adverse effects. Corticosteroids, novel agents, conventional cytotoxic agents, and high-dose chemotherapy with autotransplantation (modalities used in younger patients) are also used in older patients, although the elderly undergo transplantation less frequently. The sequential use of active agents singly and in different combinations has improved response rates and survival of all patients with myeloma, including the elderly. (Blood. 2010;116(13):2215-2223)

引用

页码：2215 / 2223

页数：9

共 47 条

[31] Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial [J].

Richardson, Paul G. ;

Sonneveld, Pieter ;

Schuster, Michael ;

Irwin, David ;

Stadtmauer, Edward ;

Facon, Thierry ;

Harousseau, Jean-Luc ;

Ben-Yehuda, Dina ;

Lonial, Sagar ;

Goldschmidt, Hartmut ;

Reece, Donna ;

Miguel, Jesus San ;

Blade, Joan ;

Boccadoro, Mario ;

Cavenagh, Jamie ;

Alsina, Melissa ;

Rajkumar, S. Vincent ;

Lacy, Martha ;

Jakubowiak, Andrzej ;

Dalton, William ;

Boral, Anthony ;

Esseltine, Dixie-Lee ;

Schenkein, David ;

Anderson, Kenneth C. .

BLOOD, 2007, 110 (10) :3557-3560

[32] A phase 2 study of bortezomib in relapsed, refractory myeloma [J].

Richardson, PG ;

Barlogie, B ;

Berenson, J ;

Singhal, S ;

Jagannath, S ;

Irwin, D ;

Rajkumar, SV ;

Srkalovic, G ;

Alsina, M ;

Alexanian, R ;

Siegel, D ;

Orlowski, RZ ;

Kuter, D ;

Limentani, SA ;

Lee, S ;

Hideshima, T ;

Esseltine, DL ;

Kauffman, M ;

Adams, J ;

Schenkein, DP ;

Anderson, KC .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26) :2609-2617

[33] Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma [J].

Richardson, PG ;

Schlossman, RL ;

Weller, E ;

Hideshima, T ;

Mitsiades, C ;

Davies, F ;

LeBlanc, R ;

Catley, LP ;

Doss, D ;

Kelly, K ;

McKenney, M ;

Mechlowicz, J ;

Freeman, A ;

Deocampo, R ;

Rich, R ;

Ryoo, JJ ;

Chauhan, D ;

Balinski, K ;

Zeldis, J ;

Anderson, KC .

BLOOD, 2002, 100 (09) :3063-3067

[34] Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma [J].

San Miguel, Jesus F. ;

Schlag, Rudolf ;

Khuageva, Nuriet K. ;

Dimopoulos, Meletios A. ;

Shpilberg, Ofer ;

Kropff, Martin ;

Spicka, Ivan ;

Petrucci, Maria T. ;

Palumbo, Antonio ;

Samoilova, Olga S. ;

Dmoszynska, Anna ;

Abdulkadyrov, Kudrat M. ;

Schots, Rik ;

Jiang, Bin ;

Mateos, Maria-Victoria ;

Anderson, Kenneth C. ;

Esseltine, Dixie L. ;

Liu, Kevin ;

Cakana, Andrew ;

van de Velde, Helgi ;

Richardson, Paul G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (09) :906-917

[35] Age is not a prognostic variable with autotransplants for multiple myeloma [J].

Siegel, DS ;

Desikan, KR ;

Mehta, J ;

Singhal, S ;

Fassas, A ;

Munshi, N ;

Anaissie, E ;

Naucke, S ;

Ayers, D ;

Spoon, D ;

Vesole, D ;

Tricot, G ;

Barlogie, B .

BLOOD, 1999, 93 (01) :51-54

[36] Antitumor activity of thalidomide in refractory multiple myeloma. [J].

Singhal, S ;

Mehta, J ;

Desikan, R ;

Ayers, D ;

Roberson, P ;

Eddlemon, P ;

Munshi, N ;

Anaissie, E ;

Wilson, C ;

Dhodapkar, M ;

Zeldis, J ;

Barlogie, B ;

Siegel, D ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571

[37]

SINGHAL S, IMMUNOMODULATI UNPUB

[38] Lenalidomide in myeloma [J].

Singhal S. ;

Mehta J. .

Current Treatment Options in Oncology, 2007, 8 (2) :154-163

[39] The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias [J].

Singhal, Seema ;

Stein, Regina ;

Vickrey, Eric ;

Mehta, Jayesh .

BLOOD, 2007, 109 (08) :3611-3612

[40] Multiple myeloma [J].

Singhal, Seema ;

Mehta, Jayesh .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06) :1322-1330

← 1 2 3 4 5 →